Glycosylation differences of an anti-VEGF monoclonal antibody (PRO-169) and its extensive comparison with Bevacizumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Glycosylation differences of an anti-VEGF monoclonal antibody (PRO-169) and its extensive comparison with Bevacizumab

Published:2023-11 Issue: Volume:84 Page:101711
ISSN:1045-1056
Container-title:Biologicals
language:en
Short-container-title:Biologicals

Author:

Quiñonez-Alvarado Mayra G.,Chávez-Hurtado Paulina^ORCID,Caro-Palomera Jesús C.,Niño-Trejo Oriana L.,Jiménez-Dolores José I.,Muñoz-Villegas Patricia^ORCID,Baiza-Durán Leopoldo,Quintana-Hau Juan D.

Publisher

Elsevier BV

Subject

Pharmacology,General Immunology and Microbiology,Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology

Reference36 articles.

1. A brief history of anti-VEGF for the treatment of ocular angiogenesis;Kim;Am J Pathol,2012

2. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial;Chakravarthy;Lancet,2013

3. Ranibizumab and bevacizumab for neovascular age-related macular degeneration;N Engl J Med,2011

4. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results: comparison of age-related macular degeneration teatments trials (CATT) research group;Martin;Ophthalmology,2012

5. Off-label use of medicines in Argentina. Who wins and who loses?;Real;Pharm Policy Law,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP